News

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Managed Healthcare Executive24m

FDA Approves First in Class Therapy for Hereditary Angioedema

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...
Medpage Today on MSN22h

RNA-Targeted Drug Approved for Preventing Hereditary Angioedema Attacks

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...
Pharmaceutical Technology on MSN8h

FDA approves Ionis’ donidalorsen for HAE attack prevention

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ RNA-targeted prophylactic treatment, Dawnzera ...
The American Journal of Managed Care1d

FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

US FDA approves Ionis' drug for rare genetic disorder

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...
MPR23h

Dawnzera Approved to Prevent Hereditary Angioedema Attacks

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.
BioSpace6h

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...
Fierce Pharma1d

Ionis steps into crowded HAE market with FDA approval for Dawnzera

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

FDA approves Ionis’ hereditary angioedema drug

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.
The Pharma Letter8h

FDA approves Ionis’ Dawnzera as first RNA-targeted therapy for HAE

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...